BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase III
Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3/30/2015
Can-Fite BioPharma (CFBI) Reports Top-Line Results From Phase II/III Trial For CF101 In Treatment Of Psoriasis 3/30/2015
Morphotek Inc. Announces Initiation Of Farletuzumab Study In Patients With First-Relapsed, Platinum-Sensitive Ovarian Cancer With Low Levels Of The Immunosuppressive CA125 Tumor Antigen 3/30/2015
Janssen Research & Development Release: New Study Published In JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time To Relapse In Patients With Schizophrenia 3/30/2015
BioDelivery Sciences International (BDSI) Clonidine Topical Gel Fails Phase III, Shares Plunge 3/30/2015
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For EZN-2279 For Treatment Of Adenosine Deaminase--Deficient Severe Combined Immunodeficiency Disease 3/30/2015
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Mexico 3/30/2015
Can-Fite BioPharma (CFBI) Files 2014 Annual Report On Form 20-F 3/30/2015
Teva (TEVA) Reinforces Leadership Position In CNS With Acquisition Of Auspex Pharmaceuticals (ASPX) 3/30/2015
Cardio3 BioSciences Successfully Completes Futility Analysis Of Lead Cardiac Cell Therapy, C-Cure(R) 3/30/2015
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/27/2015
Alnylam (ALNY) Initiates ENDEAVOUR Phase 3 Clinical Trial With Revusiran 3/27/2015
European Medicines Agency Release: Accelerated Assessment Fast-Tracks Lenvima To Benefit Patients With Thyroid Cancer 3/27/2015
NephroGenex (NRX) Announces Data On Acute Kidney Injury At National Kidney Foundation 2015 Spring Clinical Meetings 3/27/2015
Northwest Biotherapeutics (NWBO) Reports Promising Survival Data In 51 Gbm Patients Treated With Dcvax-L 3/27/2015
Galderma Announces Positive Outcome Of European Decentralised Procedure For Approval Of Soolantra (Ivermectin) Cream 10mg/G For Rosacea Patients 3/27/2015
Results Of Auspex Pharmaceuticals (ASPX)' Phase 3 Registration Trial Of SD-809 To Be Presented At American Academy of Neurology Annual Meeting 3/27/2015
Relypsa (RLYP) Presents Sub-Group Analysis From Phase 3 Study Of Patiromer FOS In Patients With Advanced Chronic Kidney Disease At 2015 National Kidney Foundation Spring Clinical Meeting 3/27/2015
Merck & Co. (MRK) Study Halted on Positive Phase III Data 3/26/2015
pSivida Corp (PSDV) Completes Targeted Enrollment Of Phase III Trial Of Medidur For Posterior Uveitis 3/26/2015
Novavax, Inc. (NVAX) Prices Public Offering Of Common Stock 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results 3/26/2015
Onxeo Expands Livatag International Phase III Clinical Trial "Relive" To 3 New Countries 3/26/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Announces First Patient Screened In Pivotal Phase 3 Clinical Trial Of Sotagliflozin 3/25/2015
Vericel (ASTM) Reports Three-Year Follow-Up Results From Phase 3 SUMMIT Extension Study Of MACI Implant 3/25/2015
TRANSGENE (ENX:TNG) Reports 2014 Financial Results And Outlines Promising Clinical Pipeline 3/25/2015
NephroGenex (NRX) Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014 3/25/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Initial Payment For RGN-259 U.S. License To ReGenTree Joint Venture 3/25/2015
ThromboGenics NV (TBGNF) Announces Positive Topline Results From OASIS Study 3/24/2015
Mast Therapeutics (MSTX) Reports Fourth Quarter And Full Year 2014 Financial Results 3/24/2015
Aerie Pharmaceuticals, Inc. (AERI) Completes Enrollment In Second Phase 3 Registration Trial (“Rocket 2”) Of Rhopressa, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma 3/24/2015
La Jolla Pharmaceutical Company (LJPC) Announces Initiation Of Phase III Clinical Trial Of LJPC-501 In Catecholamine-Resistant Hypotension 3/24/2015
LFB S.A. Receives Go Ahead From Data Monitoring Committee To Expand The Global PERSEPT Phase 3 Program Of LR769 In Hemophilia A Or B Patients With Inhibitors 3/24/2015
Can-Fite BioPharma (CFBI) Signs Multi-Million Dollar Distribution Agreement For CF101 In Canada With Cipher Pharmaceuticals (DND.TO) 3/23/2015
Cipher Pharmaceuticals (DND.TO) Acquires Canadian Rights To Novel Treatment For Psoriasis And Rheumatoid Arthritis 3/23/2015
Novartis AG (NVS) Presents Cosentyx Two-Year Efficacy And Safety Data Showing Sustainable Effect In Psoriasis Patients 3/23/2015
EXCLUSIVE: Resverlogix Corporation (RVX.TO) CEO Says Experimental Cardiac Drug Holds High Hopes, As Biotech Booms 3/20/2015
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial 3/20/2015
Nektar Therapeutics (NKTR) Cancer Drug Improves Survival But Misses Primary Endpoint, As Watchers Worry 3/20/2015
Intarcia Therapeutics, Inc. And Numab AG Sign Multi-Asset Collaboration To Develop Once-Yearly Therapies In Diabetes, Obesity, and Autoimmune Indications 3/20/2015
Anthera, Inc. Announces $3 Million Research Award From Cystic Fibrosis Foundation Therapeutics, Inc. For Development Of Sollpura - A Novel Enzyme Therapy 3/20/2015
Amgen (AMGN) Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha (evolocumab) In Japan 3/20/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Chooses PharmaCell As Contract Manufacturing Partner For Its Phase III Program In Europe 3/20/2015
Galderma Laboratories Announces Positive Phase 3 Trial Results Of Investigational Adapalene 0.3%/Benzoyl Peroxide 2.5% (0.3% A/BPO) For The Treatment Of Acne 3/20/2015
New Novartis AG (NVS) Data Show More Cosentyx-Treated Psoriasis Patients Achieved Clear Or Almost Clear Skin (PASI 90) Compared To Stelara 3/20/2015
Celgene (CELG) Release: Oral Otezla (Apremilast) Long-Term Safety And Efficacy Data In Patients With Moderate To Severe Plaque Psoriasis Presented At American Academy of Dermatology 3/20/2015
Celgene (CELG) Release: Positive Results From Phase III Study Evaluating Oral Otezla (Apremilast) Or Injectable Etanercept Versus Placebo In Patients With Moderate To Severe Plaque Psoriasis Presented At American Academy of Dermatology 3/20/2015
Sanofi (SAN.PA) Test Shows Lixisenatide Doesn't Up Cardiovascular Risk 3/19/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Establishes Manufacturing Agreement With Pharmacell B.V. For European Production Of ICT-107 For Phase 3 Registration Trial 3/19/2015
PTC Therapeutics (PTCT) And University of Pennsylvania Collaborate On Orphan Disease Research 3/19/2015
ZS Pharma (ZSPH) To Present Data From Phase 3 Trials Of ZS-9 In Presentations At The National Kidney Foundation 2015 Spring Clinical Meetings 3/19/2015
Scioderm Initiates Phase 3 Registration Trial Of Zorblisatm (SD-101), A Novel Topical Therapy For Patients With Epidermolysis Bullosa 3/19/2015
AstraZeneca PLC (AZN) Two-in-One Lung Drug Succeeds in Phase III Trial 3/19/2015
New Cholesterol Drugs From Amgen (AMGN), Sanofi (SAN.PA), Regeneron (REGN) Cut Heart Risks in Half But Questions Remain 3/18/2015
AstraZeneca PLC (AZN) Announces Positive Phase III Top-Line Results For PT003 From PINNACLE 1 And PINNACLE 2 Studies In COPD 3/18/2015
Lexicon Pharmaceuticals, Inc. (LXRX) And Ipsen (IPN.PA) Expand Their Licensing And Commercialization Agreement For Telotristat Etiprate To Include Canada 3/18/2015
Tenax Therapeutics (TENX) Announces Third Quarter Fiscal Year 2015 Financial Results 3/18/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review 3/17/2015
Pharmacyclics (PCYC) Release: Independent Data Monitoring Committee Unanimously Recommends Unblinding Of IMBRUVICA (Ibrutinib) Phase III Combination HELIOS Trial Based On Interim Analysis Showing Significant Improvement In Progression-Free Survival In Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma 3/17/2015
Sinovac Biotech Ltd. (SVA) Provides Updates On Pipeline Vaccines 3/17/2015
Collegium To Present Xtampza ER Pivotal Phase III Data At The 2015 American Academy Of Pain Medicine Annual Meeting 3/17/2015
The Lancet Publishes CSL Behring's Kcentra Phase III Data 3/17/2015
QIAGEN N.V. (QGEN) Expands Leadership In Liquid Biopsies With New Circulating Tumor Cell Technology For Development Of Companion Diagnostics 3/17/2015
Anavex (AVXL) To Participate In Phase 3 Clinical Trials Panel At AD/PD 2015 3/17/2015
Sanofi (SAN.PA), Regeneron (REGN): 18-Month Results Of ODYSSEY LONG TERM Trial With Praluent (Alirocumab) Published In The New England Journal of Medicine 3/16/2015
Amgen (AMGN) Release: New Detailed Data From Phase 3 Study Show Amgen's Repatha (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol 3/16/2015
Amgen (AMGN) Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha (evolocumab) In The The New England Journal of Medicine 3/16/2015
AcelRx (ACRX) Announces Initiation Of Pivotal Phase 3 Trial For ARX-04 3/16/2015
Anthera Pharmaceuticals, Inc. (ANTH) Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For IgA Nephropathy 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
Provectus Biopharmaceuticals Inc.’ Amended Protocol Of PV-10 For Phase III Study As Treatment For Melanoma Now Available Online 3/16/2015
Mezzion Pharma Commits To Phase 3 Clinical Trials Of Udenafil In Adolescents With A Single Functional Ventricle That Have Undergone Fontan Surgical Palliation 3/16/2015
Medivir AB (MVRBF): New Data On Simeprevir Presented At The Conference Of The Asian Pacific Association For The Study Of The Liver 3/16/2015
Baxter BioScience Corporation (BAX) Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophila A And B Patients With Inhibitors 3/13/2015
Cytokinetics, Inc. (CYTK) Announces Completion Of Enrollment In COSMIC-HF 3/13/2015
Charleston Laboratories, Inc. And Daiichi Sankyo (4568.t) Announce Completion Of A Pharmacokinetics Study On CL-108 3/12/2015
Provectus Biopharmaceuticals Inc. Updates Market On Business Developments 3/12/2015
Cynapsus Therapeutics (CYNAF) Provides Clinical And Regulatory Update For APL-130277 For The Acute Rescue Of OFF Motor Symptoms Of Parkinson’s Disease 3/12/2015
XBiotech Launches Website And Call Center To Inform Cancer Patients About New Xilonix Therapy And Phase III Clinical Study 3/12/2015
At a Top Notch Facility in SoCal, Amgen (AMGN) Works on Perfecting and Cranking Out Biosimilars 3/11/2015
PharmaEssentia And AOP Orphan Announce Completion Of Recruitment Of Pivotal Phase III Trial PROUD-PV 3/11/2015
Dr. Anita J. Chawla Joins CytRx Corporation (CYTR) Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology 3/11/2015
Takeda (TKPYY) Announces Publication In The Lancet Of A Post Hoc Analysis Of Data From The EXAMINE Cardiovascular Safety Outcomes Trial 3/10/2015
Auris Medical AG (EARS) Announces Completion Of Interim Analysis In Post-Acute Tinnitus Stratum Of TACTT3 Trial With AM-101 3/10/2015
Ocular Therapeutix, Inc. (OCUL) Reports Positive Topline Clinical Data For The First Of Two Phase 3 Clinical Trials Evaluating OTX-DP For The Treatment Of Post-Surgical Ocular Inflammation And Pain 3/10/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Telotristat Etiprate 3/9/2015
Novo Nordisk A/S (NVO) Release: New Data In Adults With Obesity Or Who Are Overweight With Comorbidities Losing At Least 5% Body Weight With Saxenda (liraglutide [rDNA origin] injection) Showed Improvement In Blood Glucose, CV Risk Factors And Quality Of Life Outcomes 3/9/2015
ContraVir Pharmaceuticals To Initiate Pivotal Phase 3 Study Of FV-100 For Prevention Of Shingles-Associated PHN 3/9/2015
CTI BioPharma, Baxter International (BAX)'s Blood Cancer Drug Meets Main Goal in Late-Stage Trial 3/9/2015
Opexa Therapeutics (OPXA) Amends Agreement With Merck Serono And Receives Additional $3 Million Payment To Support Ongoing Development Of Tcelna For Multiple Sclerosis 3/9/2015
R-Tech Ueno: The End Of A Phase 3 Clinical Study And Preliminary Findings From A Phase 3 Of Unoprostone (Development Code UF-021) For Treatment Of Retinitis Pigmentosa 3/9/2015
Trimel Pharmaceuticals (TRL.TO) Announces Natesto Abstract Presentation At The 2015 Endocrine Society Annual Meeting 3/9/2015
EXCLUSIVE: Experimental Cancer Drug From Oncoceutics Could Be Fast-Tracked, Says Exec 3/6/2015
Orexigen (OREX)'s Failure to Keep a Lid on it Prompts the FDA to Force a Second Study 3/6/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
CytoTools: European Trials On Diabetic Foot And Ulcus Cruris (Leg Ulcers) On Schedule - Delay In The Market Approval For The Wound Healing Agent Dermapro In India 3/6/2015
Catalyst Pharmaceuticals (CPRX) Announces FDA Orphan Drug Designation Of Firdapse For Treatment Of Congenital Myasthenic Syndromes 3/5/2015
AOP Orphan Pharmaceuticals AG Announces Progress Of Pivotal Phase 3 Trial PROUD-PV Applying Ropeginterferon ALFA 2B, A Novel, Long-Acting, Mono-Pegylated Interferon For Treatment Of Polycythemia Vera 3/5/2015
Chiasma Announces New Data For Investigational Octreotide Capsules 3/5/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Provides Clinical Pipeline Update And Reports 2014 Fourth Quarter And Full Year Financial Results 3/4/2015
Keryx Biopharmaceuticals (KERX) Announces Publication Of Auryxia (Ferric Citrate) Analysis In Journal Of The American Society Of Nephrology 3/4/2015
CorMedix (CRMD) Provides Multiple Strategic Business Updates 3/4/2015
Drug Approved In Pivotal Studies Using DSG, Inc.’s Fully Electronic Source Data 3/3/2015
Delcath Systems, Inc. (DCTH) Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 3/3/2015
Amgen (AMGN) Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3/3/2015
CEL-SCI (CVM) Reports 2nd Consecutive Month Of Record Patient Enrollment In 2015 For Its Phase III Head And Neck Cancer Trial 3/3/2015
Gilead (GILD)'s Harvoni Achieves 96% Cure Rate in Patients With Hepatitis C and HIV 3/2/2015
Otsuka Pharmaceutical Co., Ltd. Release: First-Ever Treatment Approved In Canada For Adults Living With ADPKD, A Life-Threatening Kidney Disease 3/2/2015
Portola Pharmaceuticals, Inc. Announces Full Results From Positive Phase 3 ANNEXA-R Study Demonstrating That Andexanet Alfa Rapidly And Significantly Reversed Anticoagulant Effect Of Factor Xa Inhibitor XARELTO 3/2/2015
Dynavax Technologies Corporation (DVAX) Announces Second Independent DSMB Recommendation To Continue Phase 3 Study Of HEPLISAV-B 3/2/2015
Amgen (AMGN) Release: Phase 3 Head-To-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis (Carfilzomib) Over Velcade (Bortezomib) In Patients With Relapsed Multiple Myeloma 3/2/2015
CEL-SCI (CVM) Completes Key Milestone With Clearance To Conduct Phase 3 Trial In 21 Countries 3/2/2015
Isis Pharmaceuticals, Inc. (ISIS) Earns $15 Million From GlaxoSmithKline (GSK) for Advancing ISIS-TTR Rx 3/2/2015
Amgen (AMGN)'s Hormone-Imbalance Drug AMG 416 Shows Positive Results in Phase 3 Study 2/27/2015
Gilead (GILD) Announces SVR12 Rates From Phase III Study Evaluating Harvoni For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV 2/27/2015
Argos Therapeutics, Inc. (ARGS) Announces Update On Phase 3 ADAPT Trial To Be Presented During 2015 ASCO Genitourinary Cancers Symposium 2/27/2015
Amgen (AMGN) Receives Positive CHMP Opinion For Use Of Vectibix (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer 2/27/2015
Biogen Idec (BIIB) And Swedish Orphan Biovitrum Announce Positive Top-Line Efficacy And Safety Results From Phase 3 ALPROLIX Pediatric Study 2/27/2015
Gilead (GILD) Announces Phase 3 Results For Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) 2/27/2015
Bristol-Myers Squibb (BMY) Release: ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected With HIV After Ribavirin-Free Investigational 12-Week Regimen Of Daclatasvir And Sofosbuvir 2/27/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Chimerix (CMRX) Provides Update On Anticipated SUPPRESS Enrollment 2/26/2015
Portola Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation For Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibitor Antidote 2/26/2015
Gradalis Inc. Announces Initiation Of A Phase 3 Registration Study For Vigil In Ovarian Cancer 2/26/2015
Bristol-Myers Squibb (BMY) Release: Study Of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results In Preventing Viral Replication Via Different Mechanism Of Action Than Current Therapies 2/26/2015
Amgen (AMGN) Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis 2/26/2015
Eisai Inc. (ESALF.PK) Release: Topline Results Of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint Of Overall Survival In Advanced Soft Tissue Sarcoma 2/25/2015
Dipexium Pharmaceuticals (DPRX) Passes 25% Enrollment In Locilex Pivotal Phase 3 Clinical Trials 2/25/2015
Nektar Therapeutics (CA) (NKTR) Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain 2/25/2015
Sunovion Pharmaceuticals Inc. Announces Initiation Of Phase 3 Clinical Trial Program For SUN-101/Eflow (Glycopyrrolate) In Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 2/25/2015
Bristol-Myers Squibb (BMY) Release: 48-Week Analysis Of Investigational HIV-1 Attachment Inhibitor Paves Way For Phase III Trial Initiation 2/25/2015
Antares Pharma, Inc. (ATRS) Announces Positive Top-Line Pharmacokinetic Results From The Quickshot Phase 3 Study In Testosterone Deficient Men 2/25/2015
Cytori Therapeutics, Inc. (CYTX) Receives Positive European Opinion On Orphan Drug Status 2/24/2015
Theravance Biopharma Enrolls First Patient In Phase 3 Registrational Study Of Telavancin In Staphylococcus Aureus Bacteremia 2/24/2015
Teva Pharmaceutical Industries (TEVA) Release: The Lancet Respiratory Medicine And AAAAI Publish Positive Data From Phase 3 Trials Of Teva’s Reslizumab For The Treatment Of Moderate To Severe Asthma In Patients With Elevated Blood Eosinophils 2/24/2015
Celsion Corporation (CLSN) Announces Updated Overall Survival Data from HEAT Study of ThermoDox In Primary Liver Cancer 2/23/2015
TiGenix's Phase III Trial Design For Cx601 Endorsed By President-Elect Of ECCO 2/23/2015
ADMA Biologics, Inc. Announces Positive Data On Primary And Secondary Endpoints From Its Pivotal Phase III Clinical Trial For RI-002 At The American Academy of Allergy, Asthma and Immunology (AAAAI) Medical Conference 2/23/2015
Hemispherx Biopharma (HEB): Institute Of Medicine, The Health Arm Of The US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) As A "Systemic Exertion Intolerance Disease" (SEID) 2/23/2015
Eli Lilly (LLY) Release: Baricitinib Superior To Placebo In Reducing Rheumatoid Arthritis Disease Activity In Second Phase 3 Study 2/23/2015
Results from AbbVie (ABBV)'s Study Of VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) Published Online In JAMA; Sub-Analyses To Be Presented At The Annual Conference On Retroviruses And Opportunistic Infections (CROI) 2/23/2015
BioTie Therapies Corp. Provides Portfolio Update On Tozadenant 2/20/2015
Pierre Fabre Release: A phase 2/3 Clinical Data Published In The NEJM Confirms Positive Safety-Efficacy Profile For First Pediatric Treatment For Infantile Hemangioma 2/20/2015
Immunomedics, Inc. (IMMU) Presents Updated Results With Sacituzumab Govitecan in Lung Cancer 2/20/2015
Actavis (ACT) Touts Potential $6 Billion Pipeline at Investor Meeting 2/19/2015
EXCLUSIVE: Chimerix (CMRX) Says 2015 Will Be "Pivotal" Year, In Talks With Regulators to Use Antiviral After Transplants 2/19/2015
Takeda (TKPYY) Lung Cancer Drug Motesanib Flunks Late Stage Trial 2/19/2015
Nuo Therapeutics Initiates Phase 4 Study Of Aurix Under CMS Coverage With Evidence Development Program 2/19/2015
Eli Lilly (LLY) Provides Update On Evacetrapib Phase 3 Trial 2/19/2015
CEL-SCI (CVM)’s Phase III Head And Neck Cancer Trial Cleared To Begin Patient Enrollment In Malaysia, The 20th Country To Join The Trial 2/19/2015
Sanofi (SAN.PA)'s Cerdelga Shows Promise in Late Stage Trial 2/18/2015
Genzyme (GENZ) Release: ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (Eliglustat) For Treatment-Naïve Patients With Gaucher Disease Type 1 Published In JAMA 2/18/2015
Elite Pharmaceuticals, Inc. (ELI) Provides Guidance On Phase III Study For ELI-200 2/18/2015
PAREXEL International (PRXL) Simplifies Patient Recruitment And Study Start-Up Timelines Through Innovative Site Alliance Network 2/18/2015
Seattle Genetics, Inc. (SGEN) Submits Supplemental BLA To FDA For Phase 3 AETHERA Trial Of ADCETRIS® (Brentuximab Vedotin) In Post-Transplant Hodgkin Lymphoma Patients At High Risk Of Relapse 2/18/2015
Takeda (TKPYY) Announces Phase 3 MONET-A Study Evaluating Motesanib (AMG 706) In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Does Not Meet Primary Endpoin 2/17/2015
Hyperion Therapeutics (HPTX) Enters Into Completion Of Phase III Clinical Trial, Option And Mutual Release Agreement With Clal Biotechnology Industries And Yeda Research and Development Company Ltd. 2/17/2015
MediVector Completes Patient Enrollment In Two Phase 3 Studies Of Favipiravir For Influenza 2/17/2015
Navidea Biopharmaceuticals (NAVB) Release: Lymphoseek Results From Phase 3 Clinical Trial In Oral Cavity Cancer Of The Head And Neck Published In Annals Of Surgical Oncology 2/17/2015
Improved Survival In Children With Graft Versus Host Disease Who Respond To Mesoblast Limited (MSB.AX)'s Cell Therapy 2/16/2015
BIOCEO15: Gilead (GILD) COO Says 6-Week Timeline for Hep C Course Unrealistic, Outlines NASH, Cancer Strategies 2/12/2015
Eisai Inc. (ESALF.PK) Release: Pivotal Phase 3 Trial of Investigational Agent Lenvatinib In Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published In New England Journal Of Medicine 2/12/2015
Genzyme (GENZ) Presents Phase 3 Clinical Trial Extension Results For Cerdelga® (Eliglustat) At Lysosomal Disease Network’s WORLD Symposium 2015 2/12/2015
Chimerix (CMRX) Presents Update On Preliminary Data From Advise Study Of Brincidofovir For Adenovirus Infection At BMT Tandem Meetings 2/12/2015
The Philippines Is The 19th Country To Clear CEL-SCI (CVM) For Patient Enrollment In Its Phase III Head And Neck Cancer Trial 2/11/2015
Baxter International, Inc. (BAX) Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-Life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A 2/11/2015
Interim Phase 3 Results Positive for Takeda (TKPYY) Blood Cancer Med Ixazomib 2/10/2015
Anthera Pharmaceuticals, Inc. (ANTH) Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For Systemic Lupus Erythematosus 2/10/2015
Amicus Therapeutics, Inc. (FOLD) Announces Additional Positive Phase 3 Fabry Data On Patient Reported Outcomes At Worldsymposium 2015 2/10/2015
AB Science (AB.PA) : Successful Completion Of Futility Test For Masitinib In Alzheimer's Disease 2/10/2015
Galena Biopharma  (GALE) Enrolls 700th Patient In Neuvax (Nelipepimut-S) Phase 3 PRESENT Clinical Trial 2/9/2015
La Jolla Pharmaceutical Company (LJPC) Announces Special Protocol Assessment For Planned Phase 3 Trial Of LJPC-501 In Catecholamine-Resistant Hypotension 2/9/2015
Provectus Biopharmaceuticals Inc. Met With FDA On Operational Aspects Of PV-10 Phase 3 Melanoma Study 2/9/2015
Chiasma Inc. Release: Newly Published Phase 3 Study Results Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder 2/9/2015
GlaxoSmithKline (GSK) And Theravance, Inc. (THRX) Announce Start Of Phase 3 Lung Function Study With 'Closed' Triple Combination Treatment FF/UMEC/VI For COPD 2/9/2015
Newly Presented Data Shows That Peregrine Pharmaceuticals, Inc. (PPHM)' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity Of Immune Checkpoint Inhibitors PD-1 And CTLA-4 In Models Of Breast Cancer And Melanoma 2/9/2015
Second Breakthrough Status Win for Genentech (RHHBY) Immunotherapy Drug 2/6/2015
GlaxoSmithKline (GSK) Touts Positive Data From Phase III COMBI-D Study 2/6/2015
Portola Pharmaceuticals, Inc.'s Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis In Phase 3 APEX Study; Trial Continues As Planned And Remains On Track For Enrollment Completion By Year-End 2/6/2015
Cognoptix CEO Paul Hartung Says Company Is Preparing For A Pivotal Phase 3 Clinical Trial Of SAPPHIRE Eye Scan Being Developed To Aid In The Early Detection Of Alzheimer’s Disease 2/5/2015
Genentech (RHHBY) Shows Off Positive Phase III Lymphoma Data From Late-Stage Study 2/5/2015
Amgen (AMGN) Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate Abp 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis 2/4/2015
Daiichi Sankyo, Inc. (4568.t) Announces First Patients In Large-Scale, Multi-National Phase 3 Clinical Programs For Mirogabalin 2/4/2015
Can-Fite BioPharma (CFBI) Completes Phase 2/3 Trial For CF101 In Treatment of Psoriasis 2/4/2015
Roche (RHHBY)’s Phase 3 Study Of Gazyva/Gazyvaro Showed Significant Benefit In Refractory Indolent Non-Hodgkin’s Lymphoma 2/4/2015
Genentech (RHHBY)’s Phase III Study Of Gazyva Showed Significant Benefit In Refractory Indolent Non-Hodgkin’s Lymphoma 2/4/2015
EXCLUSIVE: Esperion Therapeutics, Inc. (ESPR) CEO Says FDA Lift Means ETC-1002 Will Be in Phase III Trials By End of 2015 2/4/2015
Flexion Therapeutics (FLXN) Initiates Phase 3 Clinical Trial Of FX006 In Patients With Osteoarthritis Of The Knee 2/3/2015
CTI BioPharma Announces Independent DMC Recommendation To Continue GOG-0212 Phase 3 Study Of OPAXIO™ As Maintenance Therapy In Ovarian Cancer, An NRG Oncology/GOG Study 2/3/2015
Onconova Therapeutics Inc. (ONTX) Announces Clinical Development Plan For Rigosertib In Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure Of Treatment With Hypomethylating Agents (Hmas) 2/3/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 2/3/2015
FDA Grants Breakthrough Therapy Designation For Genentech (RHHBY)’s Investigational Cancer Immunotherapy MPDL3280A (Anti-PDL1) In Non-Small Cell Lung Cancer 2/2/2015
AbbVie (ABBV) Announces Top-Line Results From Phase 3 Study Of All-Oral Treatment For Hepatitis C In Japan 2/2/2015
Evoke Pharma, Inc. Outlines Progress On Clinical Program 2/2/2015
Chimerix, Inc. (CMRX) Focusing Efforts On CMV And Adenovirus Pivotal Trials 2/2/2015
Emmaus Life Sciences Phase 3 Sickle Cell Disease Trial Data Included In 2015 Highlights Of American Society of Hematology Program 2/2/2015
CEL-SCI (CVM) Reports Record Monthly Patient Enrollment In Its Phase III Head And Neck Cancer Trial 2/2/2015